124 related articles for article (PubMed ID: 38204187)
1. Chemotherapeutic metabolism presenting as a recalcitrant case of hand-foot syndrome and mucositis.
Kwan KR; Skokan S; Blesh-Boren T; Vogel J; Harter N; Ford JB
J Oncol Pharm Pract; 2024 Apr; 30(3):584-588. PubMed ID: 38204187
[TBL] [Abstract][Full Text] [Related]
2. Myelotoxicity after high-dose methotrexate in childhood acute leukemia is influenced by 6-mercaptopurine dosing but not by intermediate thiopurine methyltransferase activity.
Levinsen M; Rosthøj S; Nygaard U; Heldrup J; Harila-Saari A; Jonsson OG; Bechensteen AG; Abrahamsson J; Lausen B; Frandsen TL; Weinshilboum RM; Schmiegelow K
Cancer Chemother Pharmacol; 2015 Jan; 75(1):59-66. PubMed ID: 25347948
[TBL] [Abstract][Full Text] [Related]
3. 6-mercaptopurine dosage and pharmacokinetics influence the degree of bone marrow toxicity following high-dose methotrexate in children with acute lymphoblastic leukemia.
Schmiegelow K; Bretton-Meyer U
Leukemia; 2001 Jan; 15(1):74-9. PubMed ID: 11243403
[TBL] [Abstract][Full Text] [Related]
4. Allopurinol to Prevent Mercaptopurine Adverse Effects in Children and Young Adults With Acute Lymphoblastic Leukemia.
Kamojjala R; Bostrom B
J Pediatr Hematol Oncol; 2021 Apr; 43(3):95-100. PubMed ID: 33750748
[TBL] [Abstract][Full Text] [Related]
5. Measures of 6-mercaptopurine and methotrexate maintenance therapy intensity in childhood acute lymphoblastic leukemia.
Nielsen SN; Grell K; Nersting J; Frandsen TL; Hjalgrim LL; Schmiegelow K
Cancer Chemother Pharmacol; 2016 Nov; 78(5):983-994. PubMed ID: 27600880
[TBL] [Abstract][Full Text] [Related]
6. Prognostic importance of 6-mercaptopurine dose intensity in acute lymphoblastic leukemia.
Relling MV; Hancock ML; Boyett JM; Pui CH; Evans WE
Blood; 1999 May; 93(9):2817-23. PubMed ID: 10216075
[TBL] [Abstract][Full Text] [Related]
7. Myelotoxicity, pharmacokinetics, and relapse rate with methotrexate/6-mercaptopurine maintenance therapy of childhood acute lymphoblastic leukemia.
Schmiegelow K; Ifversen M
Pediatr Hematol Oncol; 1996; 13(5):433-41. PubMed ID: 10897815
[TBL] [Abstract][Full Text] [Related]
8. Allopurinol reverses mercaptopurine-induced hypoglycemia in patients with acute lymphoblastic leukemia.
Zhang M; Bostrom B
F1000Res; 2019; 8():176. PubMed ID: 30828444
[TBL] [Abstract][Full Text] [Related]
9. Allopurinol use during pediatric acute lymphoblastic leukemia maintenance therapy safely corrects skewed 6-mercaptopurine metabolism, improving inadequate myelosuppression and reducing gastrointestinal toxicity.
Cohen G; Cooper S; Sison EA; Annesley C; Bhuiyan M; Brown P
Pediatr Blood Cancer; 2020 Nov; 67(11):e28360. PubMed ID: 32909665
[TBL] [Abstract][Full Text] [Related]
10. Mercaptopurine/Methotrexate maintenance therapy of childhood acute lymphoblastic leukemia: clinical facts and fiction.
Schmiegelow K; Nielsen SN; Frandsen TL; Nersting J
J Pediatr Hematol Oncol; 2014 Oct; 36(7):503-17. PubMed ID: 24936744
[TBL] [Abstract][Full Text] [Related]
11. Effect of polymorphisms in transporter genes on dosing, efficacy and toxicity of maintenance therapy in children with acute lymphoblastic leukemia.
Gervasini G; de Murillo SG; Jiménez M; de la Maya MD; Vagace JM
Gene; 2017 Sep; 628():72-77. PubMed ID: 28710036
[TBL] [Abstract][Full Text] [Related]
12. Toxic epidermal necrolysis following combination of methotrexate and trimethoprim-sulfamethoxazole.
Yang CH; Yang LJ; Jaing TH; Chan HL
Int J Dermatol; 2000 Aug; 39(8):621-3. PubMed ID: 10971734
[TBL] [Abstract][Full Text] [Related]
13. Maintenance therapy and risk of osteonecrosis in children and young adults with acute lymphoblastic leukemia: a NOPHO ALL2008 sub-study.
Toksvang LN; Andrés-Jensen L; Rank CU; Niinimäki R; Nersting J; Nielsen SN; Mogensen SS; Harila-Saari A; Abrahamsson J; Joelsson J; Overgaard UM; Quist-Paulsen P; Griškevičius L; Jónsson ÓG; Vaitkevičienė G; Frandsen TL; Toft N; Grell K; Schmiegelow K
Cancer Chemother Pharmacol; 2021 Nov; 88(5):911-917. PubMed ID: 34145469
[TBL] [Abstract][Full Text] [Related]
14. Methotrexate/6-mercaptopurine maintenance therapy influences the risk of a second malignant neoplasm after childhood acute lymphoblastic leukemia: results from the NOPHO ALL-92 study.
Schmiegelow K; Al-Modhwahi I; Andersen MK; Behrendtz M; Forestier E; Hasle H; Heyman M; Kristinsson J; Nersting J; Nygaard R; Svendsen AL; Vettenranta K; Weinshilboum R;
Blood; 2009 Jun; 113(24):6077-84. PubMed ID: 19224761
[TBL] [Abstract][Full Text] [Related]
15. Oral methotrexate/6-mercaptopurine may be superior to a multidrug LSA2L2 Maintenance therapy for higher risk childhood acute lymphoblastic leukemia: results from the NOPHO ALL-92 study.
Schmiegelow K; Heyman M; Kristinsson J; Mogensen UB; Rosthøj S; Vettenranta K; Wesenberg F; Saarinen-Pihkala U;
J Pediatr Hematol Oncol; 2009 Jun; 31(6):385-92. PubMed ID: 19648786
[TBL] [Abstract][Full Text] [Related]
16. Maintenance Treatment With Low-Dose Mercaptopurine in Combination With Allopurinol in Children With Acute Lymphoblastic Leukemia and Mercaptopurine-Induced Pancreatitis.
Zerra P; Bergsagel J; Keller FG; Lew G; Pauly M
Pediatr Blood Cancer; 2016 Apr; 63(4):712-5. PubMed ID: 26878433
[TBL] [Abstract][Full Text] [Related]
17. Mercaptopurine metabolite levels are predictors of bone marrow toxicity following high-dose methotrexate therapy of childhood acute lymphoblastic leukaemia.
Vang SI; Schmiegelow K; Frandsen T; Rosthøj S; Nersting J
Cancer Chemother Pharmacol; 2015 May; 75(5):1089-93. PubMed ID: 25788208
[TBL] [Abstract][Full Text] [Related]
18. Severe Recurrent Nocturnal Hypoglycemia During Chemotherapy With 6-mercaptopurine in 2 Children With Acute Lymphoblastic Leukemia.
Albiroty K; Al Sabahi A
J Pediatr Hematol Oncol; 2023 Apr; 45(3):162-163. PubMed ID: 36706266
[TBL] [Abstract][Full Text] [Related]
19. Excellent long-term survival of children with Down syndrome and standard-risk ALL: a report from the Children's Oncology Group.
Matloub Y; Rabin KR; Ji L; Devidas M; Hitzler J; Xu X; Bostrom BC; Stork LC; Winick N; Gastier-Foster JM; Heerema NA; Stonerock E; Carroll WL; Hunger SP; Gaynon PS
Blood Adv; 2019 Jun; 3(11):1647-1656. PubMed ID: 31160295
[TBL] [Abstract][Full Text] [Related]
20. Prevalence of TPMT, ITPA and NUDT 15 genetic polymorphisms and their relation to 6MP toxicity in north Indian children with acute lymphoblastic leukemia.
Khera S; Trehan A; Bhatia P; Singh M; Bansal D; Varma N
Cancer Chemother Pharmacol; 2019 Feb; 83(2):341-348. PubMed ID: 30474703
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
